Erythrocytic sorbitol contents in diabetic patients correlate with blood aldose reductase protein contents and plasma glucose levels, and are normalized by the potent aldose reductase inhibitor fidarestat (SNK-860)

Journal of Diabetes and its Complications

Volumn 18, Issue 6, 2004, Pages 336-342

  Asano, Tomoichiro ^a   Saito, Yasushi ^b   Kawakami, Masanobu ^c   Yamada, Nobuhiro ^d   Sekino, Hisakuni ^e   Hasegawa, Setsuo ^e  

^a UNIVERSITY OF TOKYO   (Japan)

^b CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c JICHI MEDICAL UNIVERSITY   (Japan)

^d UNIVERSITY OF TSUKUBA   (Japan)

^e Sekino Clinical Pharmacology Clinic   (Japan)

Author keywords

Aldose reductase inhibitor; Diabetes; Diabetic neuropathy; Epalrestat; Erythrocytic sorbitol; Fidarestat

Indexed keywords

ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; FIDARESTAT; GLUCOSE; SORBITOL;

ADULT; AGED; ARTICLE; CELL LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DIET RESTRICTION; ENZYME BLOOD LEVEL; ERYTHROCYTE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTPRANDIAL STATE; PRIORITY JOURNAL;

ALDEHYDE REDUCTASE; BLOOD GLUCOSE; DIABETES MELLITUS; ENZYME INHIBITORS; ERYTHROCYTES; HUMANS; IMIDAZOLIDINES; REFERENCE VALUES; REGRESSION ANALYSIS; SORBITOL;

EID: 8644251442     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diacomp.2004.04.003     Document Type: Article

References (22)

1. Asano T., Saito Y., Kawakami M., Yamada N. Fidarestat Clinical Pharmacology Study Group Fidarestat (SNK-860), a potent aldose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients. Journal of Diabetes and Its Complications. 16:2002;133-138
2. Gabbay K.H. Hyperglycemia, polyol metabolism, and complications of diabetes mellitus. Annual Review of Medicine. 26:1975;521-536
3. Gabbay K.H., Merola L.O., Field R.A. Sorbitol pathway: presence in nerve and cord with substrate accumulation in diabetes. Science. 151:1966;209-210
4. Hamada Y., Kitoh R., Raskin P. Crucial role of aldose reductase activity and plasma glucose level in sorbitol accumulation in erythrocytes from diabetic patients. Diabetes. 40:1991;1233-1240
5. Ho E.C.M., Lam K.S.L., Chung S.S.M., Chung S.K. Aldose reductase-deficient mice are alleviated from the depletion of GSH in the peripheral nerve and MNCV deficit associated with diabetes. Diabetes. 50(Suppl. 2):2001;A59
6. Hotta N., Toyoda T., Matsuoka K., Shigeta Y., Kikkawa R., Kaneko T., Takahashi A., Sugimura K., Koike Y., Ishii J., Sakamoto N. the SNK-860 Diabetic Neuropathy Study Group Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care. 24:2001;1776-1782
7. Kamon N., Mabuchi H., Takeda R., Terashima H. Effects of aldose reductase inhibitor (ONO-2235) on human erythrocyte sorbitol concentrations in 75 g oral glucose tolerance tests. Hormone and Metabolic Research. 23:1991;226-229
8. Kracke G.R., Preston G.G., Stanley T.H. Identification of a sorbitol permease in human erythrocytes. American Journal of Physiology. 266(2 Pt 1):1994;C343-C350
9. Malone J.I., Knox G., Benford S., Tedesco T.A. Red cell sorbitol. An indicator of diabetic control. Diabetes. 29:1980;861-864
10. Malone J.I., Leavengood H., Peterson M.J., O'Brien M.M., Page M.G., Aldinger C.E. Red blood cell sorbitol as an indicator of polyol pathway activity. Inhibition by sorbinil in insulin-dependent diabetic subjects. Diabetes. 33:1984;45-49
11. Mizuno K., Kato N., Makino M., Suzuki T., Shindo M. Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy. Journal of Diabetes and Its Complications. 13:1999;141-150
12. Nishimura C., Hamada Y., Tachikawa I., Gui T., Tsubouchi T., Hotta N., Tanimoto T., Urakami T. Enzyme immunoassay for aldose reductase. Clinical Chemistry. 40:1994;889-894
13. Oates P.J. Polyol pathway and diabetic peripheral neuropathy. International Review of Neurobiology. 50:2002;325-392
14. Pfeifer M.A., Schumer M.P. Clinical trials of diabetic neuropathy: past, present, and future. Diabetes. 44:1995;1355-1361
15. Raskin P., Rosenstock J. Aldose reductase inhibitors and diabetic complications. American Journal of Medicine. 83:1987;298-306
16. Shigeta H., Nakano K., Nakai M., Mori H., Shigeta M., Takagi S., Kitagawa Y., Kajiyama S., Kano Y., Arai Y., Inoue Y., Kanatsuna T., Kondo M. The effect of ONO-2235 on the sorbitol content of erythrocytes in patients with diabetic neuropathy. Sakamoto N., Kinoshita J.H., Kador P.F., Hotta N. Polyol pathway and its role in diabetic complications. 1988;553-558 Elsevier Science Publisher BV, Amsterdam
17. Sima A.A.F., Bril V., Nathaniel V., McEwen T.A.J., Brown M.B., Lattimer S.A., Greene D.A. Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. New England Journal of Medicine. 319:1988;548-555
18. Sobajima H., Aoki T., Sassa H., Suzuki T., Taniko K., Makino M., Mizuno K., Suzuki T. Pharmacological properties of fidarestat, a potent aldose reductase inhibitor, clarified by using sorbitol in human and rat erythrocytes. Pharmacology. 62:2000;193-199
19. Srivastava S.K., Hair G.A., Das B. Activated and unactivated forms of human erythrocyte aldose reductase. Proceedings of the National Academy of Sciences of the United States of America. 82:1985;7222-7226
20. The DCCT Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine. 329:1993;977-986
21. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 20:1997;1183-1197
22. The UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 352:1998;837-853